Havrix 0.5ml Vaccine

Havrix 0.5ml Vaccine contains Inactivated Hepatitis A Vaccine as an active ingredient. This vaccine is used to protect against hepatitis A that is a serious liver disease caused by the hepatitis A virus (HAV). This infection spreads via contact with contaminated water or food. It is administered by a doctor as 2 shots in the form of injection, 6 to 12 months apart and both are needed for long-term protection. Vaccination is the best way to prevent hepatitis A.

• Prevention of Hepatitis A infection

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Havrix 0.5ml Vaccine can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:

• Injection site reactions (pain, swelling, redness)
• Headache
• Irritation
• Drowsiness
• Loss of appetite

Seek medical attention in case of any unusual or severe side effects immediately.

• Havrix 0.5ml Vaccine is administered by a doctor as 2 shots in the form of injection, 6 to 12 months apart. This vaccination is done in children at the age of 12 months or older.
• Also, adults who have not been vaccinated before and want to be protected against hepatitis A can get the vaccine. It is essential to take both shots of vaccine to get the full benefit. However, the number of shots also depends on the type of vaccine.
  
  

• Havrix 0.5ml Vaccine contains Inactivated Hepatitis A Vaccine as an active ingredient. It works by activating the immune system to produce antibodies that will fight & damage the virus and destroy hepatitis A infection.
• It can be given from children at the age of 12 months to older. Vaccination is the best way to prevent hepatitis A.

• Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., & André, F. E. (1995). Clinical experience with an inactivated hepatitis A vaccine. Journal of infectious diseases, 171(Supplement_1), S44-S49. https://pubmed.ncbi.nlm.nih.gov/7876648/
• Pellegrini, V., Fineschi, N., Matteucci, G., Marsili, I., Nencioni, L., Puddu, M. ... & Zuckerman, A. J. (1993). Preparation and immunogenicity of an inactivated hepatitis A vaccine. Vaccine, 11(3), 383-387. https://pubmed.ncbi.nlm.nih.gov/8383387/
• Duff, B., & Duff, P. (1998). Hepatitis A vaccine: ready for prime time. Obstetrics & Gynecology, 91(3), 468-471. https://www.sciencedirect.com/science/article/abs/pii/S0029784497006698
• Fukushima, S., Kiyohara, T., Ishii, K., Nakano, T., & Hamada, A. (2017). Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries. Vaccine, 35(47), 6412-6415. https://pubmed.ncbi.nlm.nih.gov/29029942/
• Kaltenböck, A., Dubischar-Kastner, K., Eder, G., Jilg, W., Klade, C., Kollaritsch, H., ... & Schuller, E. (2009). Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX® 1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine, 27(33), 4483-4489. https://pubmed.ncbi.nlm.nih.gov/19486955/